APL-102

APL-102 is an oral, small molecule multi-kinase inhibitor (MTKi) developed by Apollomics for the treatment of cancer. It targets several key oncogenic drivers by inhibiting both receptor tyrosine kinases (RTKs) and serine/threonine kinases. Its primary mechanisms include inhibition of angiogenesis via vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors (PDGFRs), and the mitogen-activated protein kinase (MAPK) pathway through B-RAF and C-RAF. Additional targets include RET, CSF1R, DDR1, and c-KIT. Preclinical studies have shown that APL-102 can increase T-cell infiltration while reducing tumor-associated macrophages in the tumor microenvironment. The drug has demonstrated antitumor activity as a single agent and in combination with anti-PD1 antibodies in preclinical models[1][3][5][6][8].